Granted Patent
B2
US 12,240,876 · App. 18/311,082 · Granted Mar 4, 2025
Liver-specific Wnt signal enhancing molecules and uses thereof
Inventors:
Yang Li (Mountain View, CA); Zhengjian Zhang (Albany, CA); Randall J. Brezski (Alameda, CA); Leonard Presta (San Francisco, CA); Thomas Lopez (Palo Alto, CA); Hui Chen (Foster City, CA); Helene Baribault (Redwood City, CA); Wen-Chen Yeh (Belmont, CA); Shengjiang Tu (Foster City, CA)
Assignee:
Surrozen Operating, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.
Claims (21)
1. A liver-specific Wingless-related integration site (Wnt) signal enhancing molecule, or a pharmaceutically acceptable salt thereof, comprising:
(a) a first domain comprising two modified human R-spondin 2 polypeptides, wherein the modified R-spondin 2 polypeptides comprise amino acid substitutions at positions F105 and F109 of SEQ ID NO:48, or fragments thereof comprising the furin 1 and furin 2 domains of the modified human R-spondin 2 polypeptides, wherein the first domain specifically binds one or more-transmembrane E3 ubiquitin ligases, wherein the one or more transmembrane E3 ubiquitin ligases are Zinc and Ring Finger 3 (ZNRF3) and Ring Finger Protein 43 (RNF43); and
(b) a second domain comprising an Immunoglobulin G (IgG) antibody comprising two heavy chain polypeptides and two light chain polypeptides, wherein the heavy chain polypeptides comprise a CDRH1 sequence of SYAMS (SEQ ID NO: 34), a CDRH2 sequence of AISGSGGSTYYAESVKG (SEQ ID NO: 63), and a CDRH3 sequence of DFSSRRWYLEY (SEQ ID NO: 36), and the light chain polypeptides comprise a CDRL1 sequence of QGESLRSYYAS (SEQ ID NO: 37), a CDRL2 sequence of YGKSNRPS (SEQ ID NO: 38), and a CDRL3 sequence of CTSLERIGYLSYV (SEQ ID NO: 39), wherein the second domain specifically binds a tissue-specific cell surface molecule, wherein the tissue specific cell surface molecule is an asialoglycoprotein receptor I (ASGRI),
wherein the first modified human R-spondin 2 polypeptides or fragments thereof of the first domain is fused to the N-terminus of the first heavy chain polypeptides of the second domain, and the second modified human R-spondin 2 polypeptide or fragment thereof of the first domain is fused to the N-terminus of the second heavy chain polypeptide of the second domain.
2. The molecule of claim 1 , wherein the amino acid substitutions at positions F105 and F109 are: F105E and F109E.
3. The molecule of claim 1 , comprising two antibody light chain polypeptides and two fusion polypeptides, wherein each fusion polypeptide comprises the modified human R-spondin 2 polypeptide or fragment thereof fused to the N-terminus of the IgG antibody heavy chain polypeptide via a peptidyl linker sequence, wherein the two fusion polypeptides are linked to each other, and the two antibody light chain polypeptides are each linked to different heavy chain polypeptides of the fusion polypeptides.
4. The molecule of claim 3 , wherein the peptidyl linker sequences comprise one or more amino acids selected from the group consisting of: Glycine, Asparagine, Serine, Threonine and Alanine.
5. A pharmaceutical composition comprising the molecule of claim 1 and a pharmaceutically acceptable diluent, adjuvant or carrier.
6. The molecule of claim 3 , wherein:
(i) the two antibody light chain polypeptides comprise a variable region sequence having at least 95% identity to the variable region sequence set forth in SEQ ID NO: 27; and/or
(ii) the two antibody heavy chain polypeptides comprise a variable region sequence having at least 95% identity to the variable region sequence set forth in amino acids 123-242 of SEQ ID NO: 8.
7. The molecule of claim 1 comprising:
(i) two polypeptides having at least 95% identity to SEQ ID NO: 7; and
(ii) two polypeptides having at least 95% identity to SEQ ID NO: 8.
8. The molecule of claim 6 , comprising:
(i) two polypeptides of SEQ ID NO: 7; and
(ii) two polypeptides of SEQ ID NO: 8.
9. A pharmaceutical composition comprising the molecule of claim 7 and a pharmaceutically acceptable diluent, adjuvant or carrier.
10. The pharmaceutical composition of claim 9 , wherein the molecule comprises:
(i) two polypeptides of SEQ ID NO: 7; and
(ii) two polypeptides of SEQ ID NO: 8.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 3, 2023
From: LI, YANG; ZHANG, ZHENGJIAN; BREZSKI, RANDALL J.; PRESTA, LEONARD; LOPEZ, THOMAS; CHEN, HUI; BARIBAULT, HELENE; YEH, WEN-CHEN; TU, SHENGJIANG
To: SURROZEN OPERATING, INC.
Reel/Frame 063520/0656 →
Continuity (5)
Continuation
PCTUS2021059564
· Nov 16, 2021
Provisional Application
63248157
· Sep 24, 2021
Provisional Application
63182106
· Apr 30, 2021
Provisional Application
63114457
· Nov 16, 2020
References Cited (259)
US 4946778A
· Ladner et al.
· 1990
[cited by applicant]
US 5091513A
· Huston et al.
· 1992
[cited by applicant]
US 5132405A
· Huston et al.
· 1992
[cited by applicant]
US 6528624B1
· Idusogie et al.
· 2003
[cited by applicant]
US 6538124B1
· Idusogie et al.
· 2003
[cited by applicant]
US 7297775B2
· Idusogie et al.
· 2007
[cited by applicant]
US 7317091B2
· Lazar et al.
· 2008
[cited by applicant]
US 7364731B2
· Idusogie et al.
· 2008
[cited by applicant]
US 7657380B2
· Lazar et al.
· 2010
[cited by applicant]
US 7662925B2
· Lazar et al.
· 2010
[cited by applicant]
US 8278036B2
· Kariko et al.
· 2012
[cited by applicant]
US 8507442B2
· Gurney et al.
· 2013
[cited by applicant]
US 8691966B2
· Kariko et al.
· 2014
[cited by applicant]
US 8748089B2
· Kariko et al.
· 2014
[cited by applicant]
US 8835108B2
· Kariko et al.
· 2014
[cited by applicant]
US 8969526B2
· Baehner et al.
· 2015
[cited by applicant]
US 9296826B2
· Cong et al.
· 2016
[cited by applicant]
US 9771427B2
· Hofer et al.
· 2017
[cited by applicant]
US 20030044409A1
· Carson et al.
· 2003
[cited by applicant]
US 20080267955A1
· Schluesener et al.
· 2008
[cited by applicant]
US 20100092457A1
· Aburatani et al.
· 2010
[cited by applicant]
US 20140044713A1
· De Lau et al.
· 2014
[cited by applicant]
US 20160303232A1
· Adiwijaya et al.
· 2016
[cited by applicant]
US 20170158775A1
· Linden et al.
· 2017
[cited by applicant]
US 20170349659A1
· Garcia et al.
· 2017
[cited by applicant]
US 20180066067A1
· Cong et al.
· 2018
[cited by applicant]
US 20200199237A1
· Garcia et al.
· 2020
[cited by applicant]
US 20200199238A1
· Garcia et al.
· 2020
[cited by applicant]
US 20210292422A1
· Li
· 2021
[cited by applicant]
US 20210403578A1
· Garcia et al.
· 2021
[cited by applicant]
US 20220064337A1
· Li et al.
· 2022
[cited by applicant]
US 20220112278A1
· Li et al.
· 2022
[cited by applicant]
US 20220175884A1
· Lee et al.
· 2022
[cited by applicant]
US 20220195053A1
· Li et al.
· 2022
[cited by applicant]
US 20230138045A1
· Li
· 2023
[cited by applicant]
US 20230183359A1
· Garcia et al.
· 2023
[cited by applicant]
US 20240279303A1
· Zhang et al.
· 2024
[cited by applicant]
CN 104080471A
· 2014
[cited by applicant]
CN 104704001A
· 2015
[cited by applicant]
CN 106714831A
· 2017
[cited by applicant]
CN 108602888A
· 2018
[cited by applicant]
EP 2305274A1
· 2011
[cited by applicant]
EP 2331136B1
· 2018
[cited by applicant]
WO WO2004063351A2
· 2004
[cited by applicant]
WO WO2006079372A1
· 2006
[cited by applicant]
WO WO2006088494A2
· 2006
[cited by applicant]
WO WO2006105338A2
· 2006
[cited by applicant]
WO WO2007024249A2
· 2007
[cited by applicant]
WO WO2008093646A1
· 2008
[cited by applicant]
WO WO2010090513A2
· 2010
[cited by applicant]
WO WO2010092457A1
· 2010
[cited by applicant]
WO WO2011130624A2
· 2011
[cited by applicant]
WO WO2012014076A2
· 2012
[cited by applicant]
WO WO2012045075A1
· 2012
[cited by applicant]
WO WO2012138453A1
· 2012
[cited by applicant]
WO WO2012140274A2
· 2012
[cited by applicant]
WO WO2013052523A1
· 2013
[cited by applicant]
WO WO2013054307A2
· 2013
[cited by applicant]
WO WO2013071047A1
· 2013
[cited by applicant]
WO WO2013078199A2
· 2013
[cited by applicant]
WO WO2013130364A1
· 2013
[cited by applicant]
WO WO2013151666A2
· 2013
[cited by applicant]
WO WO2014023709A1
· 2014
[cited by applicant]
WO WO2014081507A1
· 2014
[cited by applicant]
WO WO2014093924A1
· 2014
[cited by applicant]
WO WO2014164253A1
· 2014
[cited by applicant]
WO WO2015164392A2
· 2015
[cited by applicant]
WO WO2016040895A1
· 2016
[cited by applicant]
WO WO2016073906A2
· 2016
[cited by applicant]
WO WO2016081640A1
· 2016
[cited by applicant]
WO WO2017069628A2
· 2017
[cited by applicant]
WO WO2017100467A2
· 2017
[cited by applicant]
WO WO2018098363A2
· 2018
[cited by applicant]
WO WO2018107116A1
· 2018
[cited by applicant]
WO WO2018132572A1
· 2018
[cited by applicant]
WO WO2018140821A1
· 2018
[cited by applicant]
WO WO2018203567A1
· 2018
[cited by applicant]
WO WO2018215614A1
· 2018
[cited by applicant]
WO WO2019126398A1
· 2019
[cited by applicant]
WO WO2019126399A1
· 2019
[cited by applicant]
WO WO2019126401A1
· 2019
[cited by applicant]
WO WO2020010308A1
· 2020
[cited by applicant]
WO WO2020014271A1
· 2020
[cited by applicant]
WO WO2020132356A1
· 2020
[cited by applicant]
WO WO2020167848A1
· 2020
[cited by applicant]
WO WO2020185960A1
· 2020
[cited by applicant]
WO WO2020206005A1
· 2020
[cited by applicant]
WO WO2020250156A1
· 2020
[cited by applicant]
WO WO2021003054A1
· 2021
[cited by applicant]
WO WO2021173726A1
· 2021
[cited by applicant]
WO WO2022104280A1
· 2022
[cited by applicant]
WO WO2022192445A1
· 2022
[cited by applicant]
WO WO2023044348A1
· 2023
[cited by applicant]
WO WO2023115048A1
· 2023
[cited by applicant]
Apte, U. et al. (Sep. 2009) Beta-catenin activation promotes liver regeneration after acetaminophen-induced injury. The American Journal of Pathology. 175(3):1056-1065. DOI: 10.2353/ajpath.2009.080976.
[cited by applicant]
Arumugam, T. et al. (Apr. 2015) “New Blocking Antibodies against Novel AGR2-C4.4A Pathway Reduce Growth and Metastasis of Pancreatic Tumors and Increase Survival in Mice” Molecular Cancer Therapeutics, 14(4):941-951.
[cited by applicant]
Bhanot, P. et al. (Jul. 18, 1996) “A new member of the frizzled family from Drosophila functions as a Wingless receptor” Nature, 382:225-230.
[cited by applicant]
Bhushan, B. et al. (Nov. 2014) Pro-regenerative signaling after acetaminophen-induced acute liver injury in mice identified using a novel incremental dose model. The American Journal of Pathology. 184(11):3013-3025. DOI…
[cited by applicant]
Brott, B.K. and S.Y. Sokol (Sep. 2002) “Regulation of Wnt/LRP Signaling by Distinct Domains of Dickkopf Proteins” Mol Cell Biol, 22(17):6100-6110.
[cited by applicant]
Clevers, H. et al. (Oct. 3, 2014) “An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control” Science, 346(6205): 1248012-1- 1248012-7.
[cited by applicant]
Colman, P. M. “Effects of amino acid sequence changes on antibody-antigen interactions”, Research in Immunology, (Jan. 1994); 145(1):33-36.
[cited by applicant]
D'Souza, A.A. et al. (2015) “Asialoglycoprotein receptor mediated hepatocyte targeting—Strategies and applications”, Journal of Controlled Release, 203:126-139.
[cited by applicant]
Eppink, B. et al. (Dec. 1, 2015) “Abstract C21: Generation of Wnt- and mitogenic receptor binding bispecific antibodies to target cancer stem cells” AACR-NCI-EORTC International Conference: Molecular Targets and Cancer …
[cited by applicant]
Ettenberg S.A. et al. (Aug. 31, 2010) “Inhibition of tumorigenesis driven by different Wnt proteins requires blockade of distinct ligand-binding regions by LRP6 antibodies” Proc Natl Acad Sci USA, 107(35):15473-15478.
[cited by applicant]
GenBank Accession No. AF177394.2 “
[cited by applicant]
GenBank Accession No. AF177395.1 “
[cited by applicant]
GenBank Accession No. NM_001466.4 “
[cited by applicant]
GenBank Accession No. NM_002335.2 “
[cited by applicant]
GenBank Accession No. NM_002336.2 “
[cited by applicant]
GenBank Accession No. NM_003391.3 “
[cited by applicant]
GenBank Accession No. NM_003392.7 “
[cited by applicant]
GenBank Accession No. NM_003393.4 “
[cited by applicant]
GenBank Accession No. NM_003394.4 “
[cited by applicant]
GenBank Accession No. NM_003395.4 “
[cited by applicant]
GenBank Accession No. NM_003396.3 “
[cited by applicant]
GenBank Accession No. NM_003468.4 “
[cited by applicant]
GenBank Accession No. NM_003505.2 “
[cited by applicant]
GenBank Accession No. NM_003506.4 “
[cited by applicant]
GenBank Accession No. NM_003507.2 “
[cited by applicant]
GenBank Accession No. NM_003508.3 “
[cited by applicant]
GenBank Accession No. NM_004185.4 “
[cited by applicant]
GenBank Accession No. NM_004625.4 “
[cited by applicant]
GenBank Accession No. NM_004626.3 “
[cited by applicant]
GenBank Accession No. NM_005430.4 “
[cited by applicant]
GenBank Accession No. NM_006522.4 “
[cited by applicant]
GenBank Accession No. NM_007197.4 “
[cited by applicant]
GenBank Accession No. NM_012193.4 “
[cited by applicant]
GenBank Accession No. NM_014419.4 “
[cited by applicant]
GenBank Accession No. NM_014420.3 “
[cited by applicant]
GenBank Accession No. NM_014421.3 “
[cited by applicant]
GenBank Accession No. NM_015881.6 “
[cited by applicant]
GenBank Accession No. NM_016087.2 “
[cited by applicant]
GenBank Accession No. NM_024494.2 “
[cited by applicant]
GenBank Accession No. NM_025216.3 “
[cited by applicant]
GenBank Accession No. NM_030753.5 “
[cited by applicant]
GenBank Accession No. NM_030761.5 “
[cited by applicant]
GenBank Accession No. NM_031866.3 “
[cited by applicant]
GenBank Accession No. NM_032642.3 “
[cited by applicant]
GenBank Accession No. NM_033131.4 “
[cited by applicant]
GenBank Accession No. NM_058238.3 “
[cited by applicant]
GenBank Accession No. NM_058244.4 “
[cited by applicant]
GenBank Accession No. NM_145866.2 “
[cited by applicant]
GenBank Accession No. NP_001017403.1 “leucine-rich repeat-containing G-protein coupled receptor 6 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. NP_001017404.1 “leucine-rich repeat-containing G-protein coupled receptor 6 isoform 3 [
[cited by applicant]
GenBank Accession No. NP_001025042.2 “R-spondin-4 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. NP_001033722.1 “R-spondin-1 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. NP_001035096.1 “R-spondin-4 isoform 2 precursor [
[cited by applicant]
GenBank Accession No. NP_001193927.1 “E3 ubiquitin-protein ligase ZNRF3 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. NP_001229838.1 “R-spondin-1 isoform 2 [
[cited by applicant]
GenBank Accession No. NP_001229839.1 “R-spondin-1 isoform 3 precursor [
[cited by applicant]
GenBank Accession No. NP_001264155.1 “leucine-rich repeat-containing G-protein coupled receptor 5 isoform 2 precursor [
[cited by applicant]
GenBank Accession No. NP_001264156.1 “leucine-rich repeat-containing G-protein coupled receptor 5 isoform 3 precursor [
[cited by applicant]
GenBank Accession No. NP_001269792.1 “R-spondin-2 isoform 2 precursor [
[cited by applicant]
GenBank Accession No. NP_001292473.1 “E3 ubiquitin-protein ligase RNF43 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. NP_001292474.1 “E3 ubiquitin-protein ligase RNF43 isoform 2 [
[cited by applicant]
GenBank Accession No. NP_001304871.1 “R-spondin-2 isoform 3 [
[cited by applicant]
GenBank Accession No. NP_001333361.1 “leucine-rich repeat-containing G-protein coupled receptor 4 isoform 2 precursor [
[cited by applicant]
GenBank Accession No. NP_001662.1 “asialoglycoprotein receptor 1 isoform a [
[cited by applicant]
GenBank Accession No. NP_003658.1 “leucine-rich repeat-containing G-protein coupled receptor 5 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. NP_036374.1 “dickkopf-related protein 1 precursor [
[cited by applicant]
GenBank Accession No. NP_055236.1 “dickkopf-related protein 2 precursor [
[cited by applicant]
GenBank Accession No. NP_060233.3 “E3 ubiquitin-protein ligase RNF43 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. NP_060960.2 “leucine-rich repeat-containing G-protein coupled receptor 4 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. NP_067649.2 “leucine-rich repeat-containing G-protein coupled receptor 6 isoform 2 [
[cited by applicant]
GenBank Accession No. NP_115549.2 “E3 ubiquitin-protein ligase ZNRF3 isoform 2 [
[cited by applicant]
GenBank Accession No. NP_116173.2 “R-spondin-3 precursor [
[cited by applicant]
GenBank Accession No. NP_550436.1 “asialoglycoprotein receptor 2 isoform c [
[cited by applicant]
GenBank Accession No. NP_848660.3 “R-spondin-2 isoform 1 precursor [
[cited by applicant]
GenBank Accession No. XP_005582755.1 “Predicted: asialoglycoprotein receptor 1 isoform X1 [Macaca fascicularis]” Jan. 25, 2016, 2 pages.
[cited by applicant]
GenBank Accession No. XP_006710646.1 “R-spondin-1 isoform X1 [
[cited by applicant]
GenBank Accession No. XP_011515320.1 “R-spondin-2 isoform X1 [
[cited by applicant]
GenBank Accession No. XP_011515321.1 “R-spondin-2 isoform X2 [
[cited by applicant]
GenBank Accession No. XP_011523257.1 “E3 ubiquitin-protein ligase RNF43 isoform X1 [
[cited by applicant]
GenBank Accession No. XP_011523258.1 “E3 ubiquitin-protein ligase RNF43 isoform X2 [
[cited by applicant]
GenBank Accession No. XP_016868884.1 “R-spondin-2 isoform X3 [
[cited by applicant]
GenBank Accession No. XP_016880289.1 “E3 ubiquitin-protein ligase RNF43 isoform X1 [
[cited by applicant]
Gong, Y et al. (2010) “Wnt Isoform-Specific Interactions with Coreceptor Specify Inhibition or Potentiation of Signaling by LRP6 Antibodies” PLoS One, 5(9):e12682, doi:10.1371/journal.pone.0012682; 17 pages.
[cited by applicant]
Hao, H-X. et al. (May 10, 2012) “ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner” Nature, 485(7397):195-200.
[cited by applicant]
Heupel, W-M. et al. (Aug. 1, 2008) “Pemphigus Vulgaris IgG Directly Inhibit Desmoglein 3-Mediated Transinteraction” Journal of Immunology, 181(3):1825-1834.
[cited by applicant]
Hombach, A.A. et al. (Jan. 1, 2012) “Antibody-IL 2 fusion proteins for tumor targeting” Antibody Engineering: Methods and Protocols, 2nd Ed. Methods in Molecular Biology, vol. 907, p. 611-626.
[cited by applicant]
Ingham, P. W. (Oct. 1996) “Has the quest for a Wnt receptor finally frizzled out?” Trends Genet, 12(10):382-384.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/059564, mailed Apr. 15, 2022, 14 pages.
[cited by applicant]
Invitation to Pay Fee for International Application No. PCT/US2021/059564 dated Feb. 1, 2022, 2 pages.
[cited by applicant]
Jacobsen, B. et al. (Oct. 10, 2014) “C4.4A as a biomarker in pulmonary adenocarcinoma and squamous cell carcinoma” World Journal of Clinical Oncology, 5(4):621-632.
[cited by applicant]
Jacobsen, F.W. et al. (Feb. 3, 2017) “Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability” J Biol Chem, 292:1865-1875.
[cited by applicant]
Janda, C.Y. et al. (May 11, 2017) “Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signaling” Nature, 545(7653):234-237. HHS Public Access Author Manuscript, 35 pages.
[cited by applicant]
Jin, Y-R. and J.K. Yoon (Dec. 2012) “The R-spondin family of proteins: Emerging regulators of WNT signaling” Int J Biochem Cell Biol, 44(12):2278-2287, doi:10.1016/j.biocel.2012.09.006.
[cited by applicant]
Keerthivasan, S. et al. (Feb. 2014) “Wnt/Beta-catenin signaling in T-cells drives epigenetic imprinting of pro-inflammatory properties and promotes colitis and colon cancer” Sci Transl Med, 6(225):225ra28, doi: 10.1126/…
[cited by applicant]
Kim, K.-A. et al. (Jun. 2008) “R-Spondin Family Members Regulate the Wnt Pathway by a Common Mechanism” Mol Biol Cell, 19(6):2588-2596.
[cited by applicant]
Knight, M.N. and K. Hankenson (2014) “R-spondins: Novel matricellular regulators of the skeleton” Matrix Biology, 37:157-161.
[cited by applicant]
Krupnik, V.E. et al. (1999) “Functional and structural diversity of the human Dickkopf gene family” Gene, 238(2):301-313.
[cited by applicant]
Li, L. et al. (Feb. 22, 2002) “Second Cysteine-rich Domain of Dickkopf-2 Activates Canonical Wnt Signaling Pathway via LRP-6 Independently of Dishevelled” J Biol Chem, 277(8):5977-5981.
[cited by applicant]
Lo, M. et al. (Mar. 3, 2017) “Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice” J Biol Chem, 292:3900-3908.
[cited by applicant]
Mannstadt, M. et al. (1999) “Receptors for PTH and PTHrP: their biological importance and functional properties” American Journal of Physiology, 277:F665-F675.
[cited by applicant]
McMahon, A.P. (Jul. 1992) “The Wnt family of developmental regulators” Trends Genet, 8:236-242.
[cited by applicant]
Meier, M. et al. (2000) Crystal Structure of the Carbohydrate Recognition Domain of the HI Subunit of the Asialoglycoprotein Receptor. J Mol Biol. 300:857-865.
[cited by applicant]
Miller, J.R. (Dec. 28, 2001) “The Wnts” Genome Biol, 3(1):3001.1-3001.15.
[cited by applicant]
Moon, B-I. et al. (2015) “Functional Modulation of Regulatory T Cells by IL-2” PLoS One, 10(11):e0141864, doi:10.1371/journal.pone.0141864; 13 pages.
[cited by applicant]
Ngora, H. et al. (Feb. 2012) “Membrane-Bound and Exosomal Metastasis-Associated C4.4A Promotes Migration by Associating with the a6β4 Integrin and MT1-MMP1,2” Neoplasia, 14(2):95-107.
[cited by applicant]
Pace, L. et al. (2005) “IL-4 Modulation of CD4+ CD25+ T Regulatory Cell-Mediated Suppression” J Immunol, 174(12):7645-7653.
[cited by applicant]
Papkoff, J. et al. (May 1996) “Wnt-1 Regulates Free Pools of Catenins and Stabilizes APC-Catenin Complexes” Mol Cell Biol, 16:2128-2134.
[cited by applicant]
Paret, B. et al. (Jul. 10, 2005) “Ly6 family member C4.4A binds laminins 1 and 5, associates with Galectin-3 and supports cell migration” International Journal of Cancer, 115(5):724-733.
[cited by applicant]
Paul, W.E. (1993) “Fv Structure and Diversity in Three Dimensions” in Fundamental Immunology, 3rd ed. Raven Press, NY; Chap. 9, pp. 292-295.
[cited by applicant]
Perez De La Lastra, J.M. et al. (Apr. 1999) Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP). Immunology, vol. 96, No. 4, pp. 663-670. DOI: 10.1046/j.1365-256…
[cited by applicant]
Rudikoff, S. et al. “Single amino acid substitution altering antigen-binding specificity”, Proc Natl Acad Sci, (Mar. 1982); 79:1979-1983.
[cited by applicant]
Russell, J.O. and S. P. Monga. (2018) Wnt/beta-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology. Annu. Rev. Pathol. Mech. Dis, 13:351-378, DOI: 10.1146/annurev-pathol-020117-044010.
[cited by applicant]
Sanhueza, C.A. et al. (2017) “Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor” J Am Chem Soc, 139:3528-3536.
[cited by applicant]
Sato et al. (2011). “Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium,” Gastroenterology, 141: 1762-1772.
[cited by applicant]
Sato, T. et al. (May 14, 2009) “Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche” Nature, 459:262-265, www.nature.com/doifinder/10.1038/nature07935; with “Methods”, 1 page.
[cited by applicant]
Scatchard et al., “The attractions of proteins for small molecules and ions,” Ann. N.Y. Acad. Sci. (1949) 51:660-672.
[cited by applicant]
Shilpi, S. et al. (Jul. 2018) Drug targeting strategies for liver cancer and other liver diseases. Moj Drug Design Development & Therapy, vol. 2, No. 4, pp. 171-177.
[cited by applicant]
Skolnick J., et al., “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era,” Trends in Biotechnology, Jan. 2000, vol. 18, pp. 34-39.
[cited by applicant]
Stockert, R.J. et al. (1991) “Structural Characteristics and Regulation of the Asialoglycoprotein Receptor” Targeted Diagnostics and Therapy 4:41-64.
[cited by applicant]
Tao, Guo-Zhong et al. (Jun. 2013) Wnt/[beta]-Catenin Signaling Protects Mouse Liver against Oxidative Stress-induced Apoptosis through the Inhibition of Forkhead Transcription Factor FoxO3″ J Biol Chem, 288(24): 17214-1…
[cited by applicant]
Thomason, H.A. et al. (2010) “Desmosomes: adhesive strength and signalling in health and disease” Biochemical Journal, 429(3):419-433.
[cited by applicant]
UniProtKB, (Asgri_Human) Asialoglycoprotein receptor I. UniProtKB Accession No. P07306. Last Modified: Feb. 23, 2022. [online]. Retrieved Mar. 24, 2022 from: https://www.dot.uniprot.org/uniprot/P07306; 16 printed pages.
[cited by applicant]
UniProtKB, Membrane protein. UniProtKB Accession No. A0A0M8ZAH5. Last Modified: Dec. 9, 2015. [online]. [Retrieved on Mar. 8, 2018]. Retrieved from the Internet: URL: http://www.uniprot.org/uniproUAOAOM8ZAH5 Protein, an…
[cited by applicant]
Witzigmann, D., et al., “Variable Asialoglycoprotein Receptor 1 Expression in Liver Disease: Implications for Therapeutic Intervention,” Hepatology Research, Jun. 2016, vol. 46(7), pp. 686-696.
[cited by applicant]
Worthen, C.A. and C.A. Enns (Mar. 6, 2014) “The role of hepatic transferring receptor 2 in the regulation of iron homeostasis in the body” Frontiers in Pharmacology, 5:34, 8 pages.
[cited by applicant]
Xie, Y. et al. (Oct. 2013) “Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R-spondin” EMBO Reports, 14(12):1120-1126.
[cited by applicant]
Yan, H. et al. (Nov. 13, 2012) “Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus” eLife, 1:e00049, http://dx.doi.org/10.7554/eLife.00049; 28 pages.
[cited by applicant]
Yan, J-J. et al. (2015) “Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems” Tumor Biology, 36:55-67.
[cited by applicant]
Yang, W.H. et al. (2018) Accelerated Aging and Clearance of Host Anti-inflammatory Enzymes by Discrete Pathogens Fuels Sepsis. Cell Host Microbe. 24(4):500-513.
[cited by applicant]
Yang-Snyder, J. et al. (1996) “A frizzled homolog functions in a vertebrate Wnt signaling pathway” Curr Biol, 6:1302-1306.
[cited by applicant]
You, J. et al. (2008) “Wnt pathway-related gene expression in inflammatory bowel disease” Dig Dis Sci, 53(4):1013-1019.
[cited by applicant]
Zapata et al., “Engineering linear F(ab′)2 fragments for efficient production in
[cited by applicant]
Zhang, Z. et al. (Aug. 2020) Tissue-targeted Rspondin mimetics for liver regeneration. Scientific Reports, vol. 10, No. 1, Article 13951; DOI: 10.1038/s41598-020-70912-3, 14 pages.
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/059564, mailed May 16, 2023, 8 pages.
[cited by applicant]
Andersen et al. “Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum…
[cited by applicant]
GenBank Accession No. NP_005805.1 “cell surface A33 antigen precursor [
[cited by applicant]
Roopenian et al. “The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs” The Journal of Immunology (2003); 170(7):3528-3533.
[cited by applicant]
U.S. Appl. No. 18/896,546, filed Sep. 25, 2024, by Luca et al.
[cited by applicant]
Almagro et al. “Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy” Front Immunol. (2018); 8(1751):1-19.
[cited by applicant]
Brown et al. “Tolerance to Single, but Not Multiple, Amino Acid Replacements in Antibody VH CDR2: A Means of Minimizing B Cell Wastage from Somatic Hypermutation” The Journal of Immunology (1996); 156(9):3285-3291.
[cited by applicant]
Chiu et al. “Antibody Structure and Function: The Basis for Engineering Therapeutics” Antibodies (2019); 8(4):55, 1-80.
[cited by applicant]
Grainger et al. “Mechanisms of Wnt signaling and control” Wiley Interdiscip Rev Syst Biol Med (2018); 10(5):e1422, 1-39.
[cited by applicant]
Marvin et al. “Redesigning an antibody fragment for faster association with its antigen” Biochemistry (2003); 42(23):7077-7083.
[cited by applicant]
Cited By (1)